No effect of folic acid supplementation in the course of 1 year on haemostasis markers and C-reactive protein in older adults
article
Elevated homocysteine levels are associated with an increased cardiovascular disease (CVD) risk, but the underlying mechanism is still unclear. High homocysteine might affect the endothelium, and consequently lead to impaired haemostasis. In a randomized placebo controlled trial among 276 older adults with plasma total homocysteine concentrations above 13 mM at screening, we investigated the effect of homocysteine lowering by folic acid supplementation (0.8 mg/day) for 1 year on markers of endothelial function (von Willebrand factor), coagulation (tissue factor, factor VIIa, fragments 1+2), and fibrinolysis (fibrin degradation products, tissue-type plasminogen activator), and inflammation (C-reactive protein). Despite a 24% reduction in plasma homocysteine concentration and four-fold increase in serum folate concentration in the folic acid group compared to the placebo group, there was no clear change in any of the haemostasis markers, nor CRP. Although homocysteine is associated with vascular disease risk in the general population, marked lowering of slightly elevated homocysteine concentrations by one-year folic acid supplementation does not influence haemostasis markers. © 2005 Schattauer GmbH, Stuttgart. Chemicals / CAS: blood clotting factor 7a, 98982-74-2; C reactive protein, 9007-41-4; folic acid, 59-30-3, 6484-89-5; homocysteine, 454-28-4, 6027-13-0; thromboplastin, 9035-58-9; tissue plasminogen activator, 105913-11-9; von Willebrand factor, 109319-16-6; C-Reactive Protein, 9007-41-4; Factor VIIa, EC 3.4.21.21; Fibrin, 9001-31-4; Folic Acid, 59-30-3; Homocysteine, 454-28-4; Placebos; Thromboplastin, 9035-58-9; von Willebrand Factor
Topics
Biomedical ResearchFolic acidHaemostasisHomocysteineInterventionblood clotting factor 7aC reactive proteinfibrin degradation productfolic acidhomocysteineplacebothromboplastintissue plasminogen activatorvon Willebrand factoradultagedarticleblood clottingcardiovascular diseasecardiovascular riskclinical trialcontrolled clinical trialcontrolled studyendotheliumfemalefibrinolysisfolic acid blood levelhemostasishumaninflammationmajor clinical studymalepriority journalrandomized controlled trialvitamin supplementationAgedC-Reactive ProteinCardiovascular DiseasesDietary SupplementsFactor VIIaFemaleFibrinFolic AcidHemostasisHomocysteineHumansInflammationMaleMiddle AgedPlacebosRiskThromboplastinTime Factorsvon Willebrand Factor
TNO Identifier
238560
ISSN
03406245
Source
Thrombosis and Haemostasis, 94(1), pp. 96-100.
Pages
96-100
Files
To receive the publication files, please send an e-mail request to TNO Repository.